Antibiotic Resistance of Environmental Bacteria in Uganda ICU

Research into antibiotic resistance (ABR) in Uganda has revealed a steady increase in the prevalence of resistant clinical pathogens, highlighting a growing public health challenge. Data from a national surveillance set indicates that ABR was increasing at a rate of 0.5% per year between 2019 and 2021, with a significant surge occurring in 2021.

The increase observed in 2021 is attributed by researchers to the impact of coronavirus disease 2019 (COVID-19). This trend underscores the role of surveillance systems in generating the evidence necessary to control the spread of resistant bacteria.

Pathogen Profiles and Regional Variance

The analysis of 9,033 samples with complete metadata showed that antibiotic resistance was commonly observed in specific pathogens, notably Escherichia coli and Klebsiella pneumoniae. These findings were particularly associated with male patients and older individuals, specifically those between 61 and 70 years old.

Geographic data revealed significant disparities in resistance levels across Uganda. The highest levels of penicillin and carbapenems were detected in the northern region, while the lowest levels were found in the northeast region.

Infection Types and Multi-Drug Resistance

Multi-drug resistance (MDR) and ABR were found to be disproportionately higher in bloodstream infections compared to urinary tract infections and respiratory tract infections. These bloodstream and surgical wound infections were often caused by Acinetobacter baumannii.

The co-occurrence of various forms of ABR suggests a high level of usage of certain antibiotics across the country. Specifically, the data indicates that cephalosporins, such as ceftriaxone, are in high use throughout Uganda.

Public Health Implications

Researchers describe ABR as a silent pandemic due to its steady rise and the complexity of its association with age, gender, and specific infection types. The findings emphasize that the burden of MDR is most acute in critical clinical settings, such as those involving bloodstream infections.

Despite the overall increase in resistance, the data provides one point of relative stability: carbapenem resistance remains relatively low. This is a critical detail for healthcare providers as carbapenems are often used as last-resort treatments for severe infections.

The systematic generation of this evidence is considered essential for the implementation and evaluation of national action plans aimed at mitigating antimicrobial resistance. By characterizing the ABR profiles of priority clinical pathogens, health authorities can better understand the factors driving resistance and the patterns of antibiotic usage.

Summary of Key Findings

• ABR increased by 0.5% per year from 2019 to 2021, with a surge in 2021 linked to COVID-19.
• Resistance was most prevalent in Escherichia coli and Klebsiella pneumoniae among males aged 61-70.
• Bloodstream and surgical wound infections showed higher rates of MDR and ABR than respiratory or urinary tract infections.
• The northern region of Uganda exhibited the highest levels of penicillin and carbapenem resistance.
• High usage of ceftriaxone is suggested by the co-occurrence of ABR patterns.
• Carbapenem resistance is currently reported as remaining relatively low.